Metraipolis › archive › dc_604dcff00e74
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe — Europe PMC PMID:41578063
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41578063
- DOI
- 10.1093/oncolo/oyag014
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T08:21:19.436Z
- SHA-256 of the archived text
2912f18df261e6b4e4f3412c530cfa09ddcad9ed65458f792d763524bce98b01- Stable URL of this page
https://metraipolis.com/documento/dc_604dcff00e74
How to cite
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe — Europe PMC PMID:41578063 — Europe PMC (en), https://europepmc.org/article/MED/41578063 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_604dcff00e74 (Metraipolis archive dc_604dcff00e74, sha256 2912f18df261e6b4e4f3412c530cfa09ddcad9ed65458f792d763524bce98b01)
BibTeX
@misc{dc604dcff00e74,
title = {Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe — Europe PMC PMID:41578063},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41578063},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_604dcff00e74; sha256 2912f18df261e6b4e4f3412c530cfa09ddcad9ed65458f792d763524bce98b01},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41578063. Agents can read the archived copy with the MCP tool read_document.